Yasuyo Nose

Dr. Yasuyo Nose


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Toxins
Verified
Journal Article
Open access
PDF file
SIshigeomi Iimura
shigeomi Iimura
YNYasuyo Nose
Yasuyo Nose
KTKeiko Tabata
Keiko Tabata
KOKenji Oda
Kenji Oda
YYYoshiyuki Yamashita
Yoshiyuki Yamashita
YKYoshiaki Kawano
Yoshiaki Kawano
This postmarketing surveillance study was conducted to evaluate the safety and effectiveness of onabotulinumtoxinA in Japanese patients with laryngeal dystonia (LD). Patients receiving onabotulinumtoxinA for the first time were enrolled and observed for up to 12 months following the first injection. Safety assessment included adverse drug reactions (ADRs), and effectiveness assessments included the Voice Handicap Index-10 (VHI-10) and physician’s global assessment (PGA). ADRs were observed in 48 (5.8%) of 834 patients in the safety analysis set, including dysphonia in 43 (5.2%) patients and dysphagia in 7 (0.8%) patients. The change in total VHI-10 score (mean) in 790 patients included in the effectiveness analysis set showed that improvement in adductor LD peaked at 2 months after the first injection, while patients with abductor or mixed LD showed a gradual attenuation of effect 2–4 weeks post-injection. The change in total VHI-10 score in subsequent injections was generally similar to that following the first injection. The overall effectiveness rate according to the PGA was 93.4% (738/790 patients). The results demonstrate that onabotulinumtoxinA is a well-tolerated and effective treatment for LD in real-world clinical practice.

20 January 2025 in Kansenshogaku Zasshi
Verified
Journal Article
Open access
PDF file
YNYasuyo Nose
Yasuyo Nose
TDTakuma Danjo
Takuma Danjo
HMHiroko Mizohata
Hiroko Mizohata
AKAkemi Kaneuchi
Akemi Kaneuchi
KOKenji Oda
Kenji Oda
NTNaohiro Takahashi
Naohiro Takahashi
日本における実臨床下でのソトロビマブ(本剤)の安全性及び有効性を明らかにするための一般使用成績調査を実施した.新型コロナウイルス(SARS-CoV-2)感染症の重症化リスク因子を有し,SARS-CoV-2感染症に対して酸素投与を要せず,本剤初回使用となるSARS-CoV-2感染症患者を対象とした.観察期間は本剤投与日から最長29日間とし,29日目より前に退院・転院した入院患者では退院・転院まで,外来患者では投与当日のみとした.安全性として副作用発現状況を,有効性として入院患者におけるSARS-CoV-2感染症の疾患進行の割合(無効割合)を評価した.本剤投与14日以内を症例登録期限とする中央登録方式により,2022年1月31日から2023年2月28日までに635例が登録された.平均7.5日の観察期間に,安全性解析対象症例(外来症例142例を含む)の1.6%(10/635例;発熱7例,COVID-19肺炎2例,呼吸困難,呼吸障害,口腔内咽頭痛及び湿疹各1例)に副作用が報告された.有効性解析対象症例の無効割合は1.2%(6/489例)で,オミクロン株BA.1,BA.2,BA.5系統の優位期間の無効割合はそれぞれ1.5%(2/132例),1.0%(2/209例),1.4%(2/148例)であった.本調査の結果,当該期間における実臨床下での本剤の安全性及び有効性に新たな懸念を認めなかった.